Because the G6 and G7 smart phone apps work independently of each other, it is possible to wear both G6 and G7 at the same time. However, if a patient wears two CGM sensors at the same time the numbers might be different because they are sensing local tissue glucose levels in separate locations on the body. Dexcom recommends using either Dexcom G6 or Dexcom G7, but not both simultaneously. 

Yes, G6 will still be available to patients once G7 launches. Some patients should continue using G6 while G7 insurance coverage is expanded, and connectivity with connected insulin pumps is rolled out. 

• #1 in Accuracy¹: Dexcom G7 has an overall MARD of 8.1% for pediatrics and 8.2% for adults as published in our U.S. pivotal trial data. FreeStyle Libre 3 (L3) is FDA cleared with an overall accuracy of 8.9% for adults and 9.4% for pediatrics as listed in their U.S. User Guide^##. 

• Less Downtime^**: G7 warms up in just 30 minutes after which you can immediately make insulin dosing decisions.  L3 requires 12 hours before dosing decisions^##, which would make it unable to work with a connected system in the future. Dexcom CGM Systems adherence and persistence is nearly 30% higher with Dexcom over Libre.13 

• More Reliable: G7 has an automatic predictive low alert to help prevent a low, while L3’s threshold alerts only notify you the minute after you went low^##. 

• Medicare Support: RT-CGM is recommended for older adults, per ADA¹¹ and AACE¹² guidelines, and G6 and G7 both fulfill Medicare requirements.  L3, Abbott’s only RT-CGM, does not fulfill Medicare requirements due to the lack of a dedicated receiver. 

• Most Proven Outcomes: Dexcom generates the most amount of clinical data and has been evaluated in a greater number of studies¹ – over 300 clinical trials – on the value and benefit of CGM across the spectrum of diabetes states and methodologies to remain focused on measuring and driving the best outcomes. 

• Proven Connectivity Platform: Dexcom G7 is already part of Dexcom’s industry leading connected CGM ecosystem¹ to allow patients to manage their diabetes with the insulin and lifestyle hardware and software that works best for them.  With 4 years of proven connectivity and a saleable real-time API, Dexcom is the only CGM brand to offer AID and have a larger connectivity platform. L3 explicitly has an AID contraindication.^## 

• Overall Patient Experience: Dexcom is the #1 most recommended CGM brand by both patients and HCPs 6, #1 in patient retention7, and #1 in patient satisfaction^§§. Libre users switch to Dexcom 3x more frequently than Dexcom users switch to Libre⁸. 
  
  
  
   

  *Smart device, sold separately, required to display readings on watch. †Compatible smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility. ||Results obtained with a prior generation Dexcom CGM System. ¶Separate Follow app and internet connection required. Users should always confirm readings on the Dexcom G6 app or receiver before making treatment decisions. #Compared to a prior generation Dexcom CGM System. **Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. ††Healthcare providers can register for Dexcom Clarity at clarity.dexcom.com/professional/ registration. ‡‡An internet connection is required for patients to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility. Healthcare providers will only be able to view a patient’s glucose data if the patient elects to share it with them through Dexcom Clarity. §§Comparison of NPS scores of Dexcom, Abbott, and Medtronic, Seagrove Survey 2021 Patient Perspectives. ##Libre 3 user guide 

  1 Dexcom, data on file, 2022. 2 Beck, RW, et al. JAMA. 2017;317(4):371-378. 3 Welsh JB, et al. J Diabetes Sci Technol. Jun 13 2022:19322968221099879. 4 Dexcom G7 CGM System User Guide. 2022. 5 Managed Markets Insights & Technology, LLC. MMIT Analytics, June 2022. 6 dQ&A US Q1 2021 Diabetes Connections Patient Panel Report. 2021;69-72.  7 IQVIA, February 2022. 8 Data on File. IQVIA 2022 9 Dexcom G7 User Guide. 10 GoodRx Program: Set buy down per finance of $200 for sensors and transmitters 11 American Diabetes Association. Standards of Medical Care in Diabetes - 2023. Diabetes Care. 2023;45(S1):S1-291. 12 Grunberger G, et al. Endocr Pract. 2021;27(6):505-537. 13 IQVIA, February 2022 - According to IQVIA, patient retention data is the sum of persistent and reinitiated patients. Persistent patients are the patients who remain on therapy without interruption (days’ supply + 30-day grace period). Reinitiated patients are the group that has interruption in use. These data are for new IIT patients across all channels from September 2020 to August 2021. 

No. Dexcom G6 sensors, transmitters, and receivers are not compatible with the Dexcom G7 CGM app, sensors, nor receivers. If a compatible smart device is needed for the Dexcom G7 sensor, a patient must download the new Dexcom G7 app. The Dexcom G7 CGM system works with the existing Clarity and Follow apps.

Dexcom is working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as possible. 

Calibration is not required but conducting optional blood glucose (BG) calibrations can move your patient’s sensor reading closer to their BG meter value. 

The new Dexcom G7 CGM System requires sensors and a compatible display device. If your patient uses a compatible smart device, they will need to download the new Dexcom G7 app. An optional receiver is available as well. 

Yes, Dexcom G7 is indicated for children as young as 2 years old. 

Yes, Dexcom G7 CGM can be worn by pregnant patients with type 1, type 2 or gestational diabetes. CGM devices can be particularly beneficial for managing blood glucose levels during pregnancy, especially for those with diabetes or gestational diabetes. Dexcom G7 is for patients two years and older with any type of diabetes including type 1, type 2, or gestational diabetes. 

Advantages of patients using a CGM system during pregnancy include:

• Closer monitoring of blood sugar levels: during pregnancy, glucose levels can fluctuate often, and continuous glucose monitoring can help patients make adjustments in real-time • Reduce risk of complications: Keeping patient glucose levels in target range can help reduce the risk of pregnancy complications.^1,2

1 Yu F, et al. J Clin Endocrinol Metab. 2014.99(12).4674–4682. 2 Hapo Study Cooperative Research Group, Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008.358(19).1991-2002.

Yes, Dexcom G7 works with Dexcom Clarity.^‡‡, Healthcare professionals and patients who used Dexcom Clarity with Dexcom G6 do not need to register again. The Dexcom G7 app and receiver also conveniently integrates a Dexcom Clarity data summary for quick and easy insights. 

Pricing will vary depending on insurance coverage. Dexcom has been the #1 covered CGM brand,⁵ and our goal is to reach equal insurance coverage for Dexcom G7 as soon as possible. Dexcom will also have a quick start program allowing commercially insured patients to receive special pricing until their health plan covers it.